Halozyme Therapeutics Inc and Pfizer Inc Enter Into a Collaboration

Los Angelas, CA -- (SBWIRE) -- 12/24/2012 -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) jumped on green line after it announced on Friday that it has signed a contract with Pfizer to build up injectable versions of the drugmaker’s biotech drugs.

According to the terms of the contract, Halozyme of San Diego has settled to Pfizer, based in New York, a license to make and launch up to six products utilizing its enzyme technology. Halozyme will obtain an initial payment of $8M, which comprises the upfront fee for elite licenses to two particular drugs in primary care and specialty care, and the right for Pfizer to choose sides to four further targets after additional payments.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock’s trade at beginning with a price of $6.36 and throughout the trading session climbed at a high of $7.19 other than when day-trade ended the stock finally advanced +26.99% to $7.01.

The stock is going forward its 52 week low with 81.61% and lagging behind from its 52 week high price with -48.07%. HALO last month stock price volatility remained 5.55%.

HALO stock institutional ownership remained 68.69% while insider ownership included 3.60%. In its share capital HALO has 112.71 million outstanding shares among them 108.47 million shares have been floated in market exchange.

Should Investor Invest Money In HALO Or Wait: CLICK HERE

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com